153 related articles for article (PubMed ID: 36498736)
21. A phase II study of high-dose celecoxib and metronomic 'low-dose' cyclophosphamide and methotrexate in patients with relapsed and refractory lymphoma.
El Bary NA; Hashem T; Metwally H; Ghany AA; El Mageed HA
Hematol Oncol Stem Cell Ther; 2010; 3(1):13-8. PubMed ID: 20231809
[TBL] [Abstract][Full Text] [Related]
22. Trofosfamide in the treatment of elderly or frail patients with diffuse large B-cell lymphoma.
Witte HM; Riecke A; Mayer T; Bartscht T; Rades D; Lehnert H; Merz H; Fetscher S; Biersack H; Gebauer N
J Cancer Res Clin Oncol; 2019 Jan; 145(1):129-136. PubMed ID: 30327940
[TBL] [Abstract][Full Text] [Related]
23. Positron emission tomography-adapted therapy in low-risk diffuse large B-cell lymphoma: results of a randomized, phase III, non-inferiority trial.
Shi Q; He Y; Yi HM; Mu RJ; Jiang XF; Fu D; Dong L; Qin W; Xu PP; Cheng S; Song Q; Chen SJ; Wang L; Zhao WL
Cancer Commun (Lond); 2023 Aug; 43(8):896-908. PubMed ID: 37403255
[TBL] [Abstract][Full Text] [Related]
24. Upfront autologous hematopoietic stem cell transplantation consolidation for patients with aggressive B-cell lymphomas in first remission in the rituximab era: A systematic review and meta-analysis.
Epperla N; Hamadani M; Reljic T; Kharfan-Dabaja MA; Savani BN; Kumar A
Cancer; 2019 Dec; 125(24):4417-4425. PubMed ID: 31441943
[TBL] [Abstract][Full Text] [Related]
25. Metronomic Oral Vinorelbine: An Alternative Schedule in Elderly and Patients PS2 With Local/Advanced and Metastatic NSCLC Not Oncogene-addicted.
Rossi D; Lippe P; Rocchi MBL; Sarti D; Catalano V; Graziano F; Giordani P; Baldelli A; Fedeli SL; Imperatori L; Laici G; Cappelletti C; Tamburrano T; Bracci R; Alessandroni P
In Vivo; 2020; 34(5):2687-2691. PubMed ID: 32871800
[TBL] [Abstract][Full Text] [Related]
26. R-CVP regimen is active in frail elderly patients aged 80 or over with diffuse large B cell lymphoma.
Laribi K; Denizon N; Bolle D; Truong C; Besançon A; Sandrini J; Anghel A; Farhi J; Ghnaya H; Baugier de Materre A
Ann Hematol; 2016 Oct; 95(10):1705-14. PubMed ID: 27485454
[TBL] [Abstract][Full Text] [Related]
27. Chidamide combined with ibrutinib improved the prognosis of primary bone marrow diffuse large B cell lymphoma.
Tian C; Chen Z; Li Y
J Int Med Res; 2020 Jul; 48(7):300060520936053. PubMed ID: 32643971
[TBL] [Abstract][Full Text] [Related]
28. Aggressive lymphomas of the elderly: the DEVEC metronomic chemotherapy schedule fits the unfit.
Cox MC; Musuraca G; Battistini R; Casaroli I; Zoli V; Anticoli-Borza P; Arcari A; Naso V; di Landro F; Fabbri F; Tafuri A; Bocci G; Merli F
Br J Haematol; 2018 Dec; 183(5):819-822. PubMed ID: 29193017
[No Abstract] [Full Text] [Related]
29. Long-Term Follow-Up of a Phase II Trial of Six Cycles of Dose-Dense R-CHOP-14 for First-Line Treatment of Diffuse Large B-Cell Lymphoma in Young and Elderly Patients.
González-Barca E; Canales MA; Salar A; Ferrer S; Domingo-Domenech E; Vidal MJ; Grande C; Bargay J; Gardella S; Oriol A; Briones J; García-Frade J; Bello JL; Sánchez-Blanco JJ; Peñalver FJ; Tomás JF; Asensio A; López A; Caballero D;
Acta Haematol; 2016; 136(2):76-84. PubMed ID: 27188649
[TBL] [Abstract][Full Text] [Related]
30. Subcutaneous rituximab in patients with diffuse large B cell lymphoma and follicular lymphoma: Final results of the non-interventional study MabSCale.
Dürig J; Uhlig J; Gerhardt A; Ritter M; Hapke G; Heßling J; Staib P; Wolff F; Krumm K; von Weikersthal LF
Cancer Med; 2023 Feb; 12(3):2739-2751. PubMed ID: 36017743
[TBL] [Abstract][Full Text] [Related]
31. Rituximab and CHOP chemotherapy plus GM-CSF for previously untreated diffuse large B-cell lymphoma in the elderly: a Wisconsin oncology network study.
Chang JE; Seo S; Kim KM; Werndli JE; Bottner WA; Rodrigues GA; Sanchez FA; Saphner TJ; Longo WL; Kahl BS
Clin Lymphoma Myeloma Leuk; 2010 Oct; 10(5):379-84. PubMed ID: 21030351
[TBL] [Abstract][Full Text] [Related]
32. Reduced-dose EPOCH-R chemotherapy for elderly patients with advanced stage diffuse large B cell lymphoma.
Zhang WH; Li GY; Ma YJ; Li ZC; Zhu Y; Chang J; Hao SG; Tao R
Ann Hematol; 2018 Oct; 97(10):1809-1816. PubMed ID: 29754271
[TBL] [Abstract][Full Text] [Related]
33. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.
Abdelhamid T; Samra M; Ramadan H; Mehessin M; Mokhtar N
J Egypt Natl Canc Inst; 2011 Mar; 23(1):17-24. PubMed ID: 22099932
[TBL] [Abstract][Full Text] [Related]
34. A phase II trial of bendamustine in combination with rituximab in older patients with previously untreated diffuse large B-cell lymphoma.
Park SI; Grover NS; Olajide O; Asch AS; Wall JG; Richards KL; Sobol AL; Deal AM; Ivanova A; Foster MC; Muss HB; Shea TC
Br J Haematol; 2016 Oct; 175(2):281-289. PubMed ID: 27448091
[TBL] [Abstract][Full Text] [Related]
35. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
[TBL] [Abstract][Full Text] [Related]
36. Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma.
Chihara D; Westin JR; Oki Y; Ahmed MA; Do B; Fayad LE; Hagemeister FB; Romaguera JE; Fanale MA; Lee HJ; Turturro F; Samaniego F; Neelapu SS; Rodriguez MA; Fowler NH; Wang M; Davis RE; Nastoupil LJ
Cancer; 2016 Oct; 122(20):3145-3151. PubMed ID: 27351173
[TBL] [Abstract][Full Text] [Related]
37. Ibrutinib, rituximab, and lenalidomide in unfit or frail patients aged 75 years or older with de novo diffuse large B-cell lymphoma: a phase 2, single-arm study.
Xu PP; Shi ZY; Qian Y; Cheng S; Zhu Y; Jiang L; Li JF; Fang H; Huang HY; Yi HM; Ouyang BS; Wang L; Zhao WL
Lancet Healthy Longev; 2022 Jul; 3(7):e481-e490. PubMed ID: 36102758
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and tolerability of rituximab and reduced-dose cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy for elderly patient with diffuse large B-cell lymphoma.
Kayamori K; Shono K; Onoda M; Yokota A
Hematology; 2019 Dec; 24(1):52-59. PubMed ID: 30101679
[TBL] [Abstract][Full Text] [Related]
39. Metronomic oral vinorelbine in a real-world population of advanced non-small cell lung cancer patients.
Estevinho F; Gomes R; Hasmucrai D; Barata F
Pulmonology; 2022; 28(5):368-375. PubMed ID: 33032956
[TBL] [Abstract][Full Text] [Related]
40. [A comparative study of induction chemotherapy with or without autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed young medium/high risk diffuse large B cell lymphoma patients].
Wang X; Xia B; Wang CY; Li MZ; Xu W; Yuan T; Tian C; Zhao HF; Yang HL; Zhao ZG; Wang XF; Wang YF; Yu Y; Zhang YZ
Zhonghua Xue Ye Xue Za Zhi; 2019 Feb; 40(2):117-124. PubMed ID: 30831626
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
